Benefits: Increased growth hormone production, improved muscle mass, reduced body fat, enhanced skin quality, and better sleep patterns
doi:10.1093/nutrit/nuaa012
Fosgonimeton failed its primary endpoint in three separate clinical trials: ACT-AD (Phase 2, mild-to-moderate Alzheimers disease, June 2022)
It usually begins between the ages of 50 and 70 and is slightly more common in men than women, with a male-to-female ratio of about 1.51 (Renton et al., 2011)
(4) Similarly, the clinical study on models of diabetic neuropathic ulcers reported that GHK-Cu, combined with standard wound care, appeared more impactful for wound closure than standard care alone